• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

    65.32 +0.32 (+0.49%)
    Streaming Delayed Price Updated: 10:40 AM EST, Jan 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 464,841
    Open 65.50
    Bid (Size) 65.30 (300)
    Ask (Size) 65.52 (200)
    Prev. Close 65.00
    Today's Range 65.31 - 67.03
    52wk Range 9.570 - 76.76
    Shares Outstanding 105,736,200
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value
    The tech-heavy Nasdaq Composite faced a stark reversal on January 8, 2026, as a wave of profit-taking in high-flying artificial intelligence stocks, led by Nvidia (NASDAQ: NVDA), dragged the index... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Stocks
    News headline image
    Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    -3.6%
    -3.6%
    1 Month
    -5.1%
    -5.1%
    3 Month
    +81.1%
    +81.1%
    6 Month
    +246.3%
    +246.3%
    1 Year
    +230.7%
    +230.7%

    More News

    Read More
    Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target ↗
    Via Stocktwits
    News headline image
    Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Why Did ARWR Stock Surge Over 15% Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
    Via MarketMinute
    Topics ETFs Economy Intellectual Property
    News headline image
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today ↗
    Via The Motley Fool
    News headline image
    Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Strong Q4 2025 Revenue Beat and First FDA Approval ↗
    Via Chartmill
    News headline image
    Arrowhead (ARWR) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
    Via Benzinga
    News headline image
    FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder ↗
    Via Benzinga
    News headline image
    Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗
    Via Benzinga
    News headline image
    Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
    From Arrowhead Pharmaceuticals, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?
    Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market
    What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 65.32
    When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 01/09/26 10:40 AM ET
    What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 6.91B
    How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?
    Arrowhead Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.